Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence
- 17 November 2013
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 19 (12) , 1625-1631
Abstract
Detecting tumor recurrences early and developing therapies capable of targeting recurrences that resist frontline therapy could be of enormous benefit to patients with cancer. Using mouse tumor models, Richard Vile and colleagues find a cytokine signature associated with very early stage recurrences, as well as evidence that the recurrent tumors are resistant to innate immune responses. By targeting the altered phenotype of the recurrent tumors, the researchers cured the mice of cancer, suggesting new avenues for research into human cancer recurrence. Tumor recurrence represents a major clinical challenge. Our data show that emergent recurrent tumors acquire a phenotype radically different from that of their originating primary tumors. This phenotype allows them to evade a host-derived innate immune response elicited by the progression from minimal residual disease (MRD) to actively growing recurrence. Screening for this innate response predicted accurately in which mice recurrence would occur. Premature induction of recurrence resensitized MRD to the primary therapy, suggesting a possible paradigm shift for clinical treatment of dormant disease in which the current expectant approach is replaced with active attempts to uncover MRD before evolution of the escape phenotype is complete. By combining screening with second-line treatments targeting innate insensitivity, up to 100% of mice that would have otherwise relapsed were cured. These data may open new avenues for early detection and appropriately timed, highly targeted treatment of tumor recurrence irrespective of tumor type or frontline treatment.Keywords
This publication has 54 references indexed in Scilit:
- The role of myeloid cells in the promotion of tumour angiogenesisNature Reviews Cancer, 2008
- Dormancy and surgery‐driven escape from dormancy help explain some clinical features of breast cancerAPMIS, 2008
- Models, mechanisms and clinical evidence for cancer dormancyNature Reviews Cancer, 2007
- Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancerNature Medicine, 2007
- Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T CellsJournal of Experimental Medicine, 2003
- Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expressionInternational Journal of Cancer, 1997
- Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.1994
- T cell receptor antagonist peptides induce positive selectionCell, 1994
- The acute phase protein response during parasitic infectionImmunology Today, 1991
- The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination.Journal of Experimental Medicine, 1979